GlassScriptPhysician profile
Kevin Boyter
NPI 1326111998
$4,354.18
in general payments reported to CMS, 2019-2025
29 companies · $683 in 2025
The $683 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $1,203 · 2023: $731 · 2024: $1,154 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,461.90 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,344.48 | 2021-2025 | |
| Amgen INC. | $207.14 | 2021-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $187.41 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $144.78 | 2021-2023 | |
| Abbott Laboratories | $121.96 | 2021-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $96.85 | 2023-2024 | Gemtesa |
| Novo Nordisk INC | $87.63 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.36 | 2024 | Jardiance |
| Baxter Healthcare | $84.29 | 2022 | |
| Pfizer INC. | $83.63 | 2021-2025 | |
| Esperion Therapeutics, INC. | $53.25 | 2021 | |
| Abiomed | $46.46 | 2024 | Impella |
| Inari Medical, INC. | $46.33 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $34.10 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $30.82 | 2022 | |
| Antares Pharma, INC. | $28.79 | 2024-2025 | Xyosted |
| Medtronic, INC. | $28.50 | 2021-2022 | |
| Astellas Pharma US INC | $26.22 | 2022-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.58 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $20.37 | 2022 | |
| Amarin Pharma, INC. | $17.09 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.72 | 2024 | Caplyta |
| Glaxosmithkline, LLC. | $14.63 | 2022 | |
| Corium, LLC | $14.17 | 2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $13.89 | 2021 | |
| Lilly USA, LLC | $13.52 | 2023 | Zepbound |
| Merck Sharp & Dohme LLC | $11.71 | 2022 | |
| Acadia Pharmaceuticals INC | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Boyter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.